Vivo Bio Tech reports FY26 net loss, publishes results
Vivo Bio Tech Limited reported a consolidated net loss of ₹170.88 lakh for FY26, a reversal from the net profit of ₹728.26 lakh in the previous year, while total income increased to ₹5,377.55 lakh. The board approved the audited results, re-appointed Mr. Kalyan Ram Mangipudi as Whole-time Director, and noted outstanding statutory dues of approximately ₹419.29 lakh.
*this image is generated using AI for illustrative purposes only.
Vivo Bio Tech Limited reported a consolidated net loss of ₹170.88 lakh for the financial year ended March 31, 2026, compared to a net profit of ₹728.26 lakh in the previous year. The company's board, meeting on May 30, 2026, approved the audited standalone and consolidated financial results for the fourth quarter and fiscal year. Revenue from operations for the year rose to ₹5,377.55 lakh from ₹4,667.25 lakh in FY25. The company subsequently published these audited financial results in newspapers on June 02, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Financial Performance
For the quarter ended March 31, 2026, the company reported a consolidated net loss of ₹516.27 lakh. On a standalone basis, the net loss for the quarter was ₹543.69 lakh. Total income for the consolidated year stood at ₹5,377.55 lakh, while standalone total income was ₹5,300.93 lakh. The results were reviewed by the Audit Committee and approved by the Board.
| Financial Metric (Consolidated) | Year Ended March 31, 2026 | Year Ended March 31, 2025 |
|---|---|---|
| Total Income | ₹5,377.55 lakh | ₹4,667.25 lakh |
| Net Profit / (Loss) | (₹170.88 lakh) | ₹728.26 lakh |
| Earnings Per Share (Basic) | (₹0.82) | ₹4.76 |
Key Board Decisions
Besides the financial results, the board approved the re-appointment of Mr. Kalyan Ram Mangipudi (DIN: 02012580) as Whole-time Director. The board also considered material related party transactions, subject to shareholder approval via postal ballot. Additionally, the board appointed a consultant to advise on the proposed scheme of arrangement or amalgamation, including preparation and compliance related to the transaction.
Auditor's Observations
The statutory auditors, P. Murali & Co., issued an unmodified opinion on the financial results. However, they drew attention to the fact that the company has not been regular in depositing certain undisputed statutory dues, including Provident Fund, Employees' State Insurance, Professional Tax, Tax Deducted at Source (TDS), and Income Tax. These outstanding dues amount to approximately ₹419.29 lakh as of March 31, 2026. The auditors noted that the outcome of any proceedings or penalties for these delays is uncertain.
| Statutory Dues | Amount (Rs. In Lakhs) |
|---|---|
| Provident Fund | 60.73 |
| ESI | 6.37 |
| Professional Tax | 11.26 |
| Tax Deducted at Source | 151.29 |
| Self-Assessment Tax | 189.64 |
Operational Details
The company operates in a single segment, Bio Technology. During FY26, it allotted 50,25,812 equity shares pursuant to the conversion of warrants issued on a preferential basis. The paid-up equity share capital as of March 31, 2026, stood at ₹2,219.06 lakh. The consolidated cash and cash equivalents increased to ₹143.55 lakh from ₹128.06 lakh in the previous year.
Historical Stock Returns for Vivo Bio Tech
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.58% | -4.33% | -13.17% | -28.26% | -37.60% | -74.52% |
What specific measures will management implement to reverse the profitability trend and address the widening net losses?
How does the company plan to settle the outstanding statutory dues of ₹419.29 lakh to avoid potential regulatory penalties?
What are the strategic objectives behind the proposed scheme of arrangement or amalgamation currently being advised upon?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
